“Merck stock surged 10% Friday after it said its investigational pill cuts the risk of hospitalization and death in COVID-19 patients…The pill reduced the risk of hospitalization or death by about 50%,” Merck and its partner, Ridgeback Biotherapeutics, said in a statement Friday. “This is a phenomenal result. This is a profound game-changer to have an oral pill that had this kind of effect, this magnitude of effect in patients who are at high risk who are already symptomatic,” former FDA Commissioner Scott Gottlieb said Friday on CNBC about results of the interim analysis. “Meanwhile, shares of COVID vaccine makers …read more
Source: Sott health news feed
Thanks! Share it with your friends!
Tweet
Share
Pin It
LinkedIn
Google+
Reddit
Tumblr